Second‐line immunotherapy in new onset refractory status epilepticus

Documenti analoghi

• New onset refractory status epilepticus: Long‐term outcomes beyond seizures
  di: Poul H. Espino, et al.
  Pubblicazione: (2025)
• Trends in management of patients with new‐onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis
  di: Aurelie Hanin, et al.
  Pubblicazione: (2024)
• Metabolomic changes in adults with status epilepticus: A human case–control study
  di: Aurélie Hanin, et al.
  Pubblicazione: (2024)
• Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection‐related epilepsy syndrome) versus without prior fever: An interim analysis
  di: Anthony D. Jimenez, et al.
  Pubblicazione: (2024)
• Extreme cryptogenic new onset refractory status epilepticus/febrile infection‐related epilepsy syndrome: Evidence of profound neuroinflammation and neuronal injury
  di: Lorenzo Muccioli, et al.
  Pubblicazione: (2026)